Header Logo

Connection

Arthur Krieg to Oligodeoxyribonucleotides

This is a "connection" page, showing publications Arthur Krieg has written about Oligodeoxyribonucleotides.
Connection Strength

11.133
  1. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012 Apr; 22(2):77-89.
    View in: PubMed
    Score: 0.358
  2. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009 Mar 28; 61(3):195-204.
    View in: PubMed
    Score: 0.289
  3. Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008 Oct; 21(8):434-9.
    View in: PubMed
    Score: 0.283
  4. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother. 2009 Apr; 58(4):615-28.
    View in: PubMed
    Score: 0.283
  5. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul; 4(3):289-94.
    View in: PubMed
    Score: 0.260
  6. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun; 5(6):471-84.
    View in: PubMed
    Score: 0.241
  7. Waag DM, McCluskie MJ, Zhang N, Krieg AM. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun. 2006 Mar; 74(3):1944-8.
    View in: PubMed
    Score: 0.237
  8. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec; 27(6):460-71.
    View in: PubMed
    Score: 0.216
  9. Wang Y, Krieg AM. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. Vaccine. 2004 Jun 30; 22(20):2641-50.
    View in: PubMed
    Score: 0.211
  10. Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, W?llner M, Wader T, Liu M, Kritzler A, Krieg AM. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol. 2004 Sep; 76(3):585-93.
    View in: PubMed
    Score: 0.211
  11. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004 Mar; 6(2):88-95.
    View in: PubMed
    Score: 0.206
  12. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan; 34(1):251-62.
    View in: PubMed
    Score: 0.204
  13. Vollmer J, Jepsen JS, Uhlmann E, Schetter C, Jurk M, Wader T, W?llner M, Krieg AM. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides. 2004; 14(1):23-31.
    View in: PubMed
    Score: 0.204
  14. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, W?llner M, Tluk S, Hartmann H, Kritzler A, M?ller C, Schetter C, Krieg AM. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res. 2004; 10(6):431-8.
    View in: PubMed
    Score: 0.204
  15. Ray NB, Krieg AM. Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. Infect Immun. 2003 Aug; 71(8):4398-404.
    View in: PubMed
    Score: 0.198
  16. Blackwell SE, Krieg AM. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol. 2003 Apr 15; 170(8):4061-8.
    View in: PubMed
    Score: 0.194
  17. Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis. 2003; 35(9):653-9.
    View in: PubMed
    Score: 0.190
  18. Krieg AM, Guga P, Stec W. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003; 13(6):491-9.
    View in: PubMed
    Score: 0.190
  19. Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev. 2002 Jun; 12(3):155-64.
    View in: PubMed
    Score: 0.183
  20. Vollmer J, Janosch A, Laucht M, Ballas ZK, Schetter C, Krieg AM. Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun; 12(3):165-75.
    View in: PubMed
    Score: 0.183
  21. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol. 2002 May 01; 168(9):4711-20.
    View in: PubMed
    Score: 0.182
  22. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol. 2001 Sep 01; 167(5):2921-8.
    View in: PubMed
    Score: 0.173
  23. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000 Feb 01; 164(3):1617-24.
    View in: PubMed
    Score: 0.155
  24. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb; 12(1):35-43.
    View in: PubMed
    Score: 0.155
  25. Lemke-Miltner CD, Blackwell SE, Yin C, Krug AE, Morris AJ, Krieg AM, Weiner GJ. Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. J Immunol. 2020 03 01; 204(5):1386-1394.
    View in: PubMed
    Score: 0.155
  26. Krieg AM. CpG oligonucleotides as immune adjuvants. Ernst Schering Res Found Workshop. 2000; (30):105-18.
    View in: PubMed
    Score: 0.154
  27. Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10; 1489(1):107-16.
    View in: PubMed
    Score: 0.154
  28. Yi AK, Peckham DW, Ashman RF, Krieg AM. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol. 1999 Dec; 11(12):2015-24.
    View in: PubMed
    Score: 0.154
  29. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999 Aug 03; 96(16):9305-10.
    View in: PubMed
    Score: 0.150
  30. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, Krieg AM. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998 Mar 15; 160(6):2555-9.
    View in: PubMed
    Score: 0.136
  31. Yi AK, Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol. 1998 Feb 01; 160(3):1240-5.
    View in: PubMed
    Score: 0.135
  32. Reeman S, Gates AJ, Pulford DJ, Krieg A, Ulaeto DO. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant. Viruses. 2017 12 09; 9(12).
    View in: PubMed
    Score: 0.134
  33. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30; 94(20):10833-7.
    View in: PubMed
    Score: 0.132
  34. Krieg AM, Matson S, Cheng K, Fisher E, Koretzky GA, Koland JG. Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. Antisense Nucleic Acid Drug Dev. 1997 Apr; 7(2):115-23.
    View in: PubMed
    Score: 0.128
  35. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996 Sep 01; 157(5):1840-5.
    View in: PubMed
    Score: 0.123
  36. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 02; 93(7):2879-83.
    View in: PubMed
    Score: 0.119
  37. Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol. 1996 Jan 15; 156(2):558-64.
    View in: PubMed
    Score: 0.117
  38. Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW. CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. Int J Antimicrob Agents. 2013 Dec; 42(6):587-8.
    View in: PubMed
    Score: 0.100
  39. Rees DG, Hartley MG, Green M, Lukaszewski RA, Griffin KF, Atkins HS, Lyons R, Krieg AM, Titball RW. The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. Microb Pathog. 2013 Oct; 63:16-8.
    View in: PubMed
    Score: 0.098
  40. La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012 Apr 15; 205(8):1294-304.
    View in: PubMed
    Score: 0.090
  41. Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, Krieg AM, Titball RW, Bancroft GJ. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis. 2011 Aug 15; 204(4):636-44.
    View in: PubMed
    Score: 0.086
  42. Krieg AM, Gmelig-Meyling F, Gourley MF, Kisch WJ, Chrisey LA, Steinberg AD. Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev. 1991; 1(2):161-71.
    View in: PubMed
    Score: 0.083
  43. Nichani AK, Dar MA, Mirakhur KK, Krieg AM, Booth JS, Townsend HG, Potter AA, Babiuk LA, Mutwiri GK. Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. Comp Immunol Microbiol Infect Dis. 2010 Dec; 33(6):e111-7.
    View in: PubMed
    Score: 0.080
  44. Richardt-Pargmann D, Wechsler M, Krieg AM, Vollmer J, Jurk M. Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. Immunobiology. 2011 Jan-Feb; 216(1-2):12-23.
    View in: PubMed
    Score: 0.079
  45. Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides. 2010 Apr; 20(2):93-101.
    View in: PubMed
    Score: 0.079
  46. Wang Y, Blozis SA, Lederman M, Krieg A, Landay A, Miller CJ. Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol. 2009 Apr; 16(4):499-505.
    View in: PubMed
    Score: 0.073
  47. Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, Worsham PL, Powell BS, Norris SL, Krieg AM, Adamovicz JJ. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine. 2009 Apr 06; 27(16):2220-9.
    View in: PubMed
    Score: 0.073
  48. Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine. 2008 Sep 02; 26(37):4849-59.
    View in: PubMed
    Score: 0.070
  49. Dar A, Nichani AK, Benjamin P, Lai K, Soita H, Krieg AM, Potter A, Babiuk LA, Mutwiri GK. Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFNalpha-producing cells and TLR9 mRNA expression. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):324-36.
    View in: PubMed
    Score: 0.068
  50. Stewart VA, McGrath S, Krieg AM, Larson NS, Angov E, Smith CL, Brewer TG, Heppner DG. Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin Vaccine Immunol. 2008 Feb; 15(2):221-6.
    View in: PubMed
    Score: 0.067
  51. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007 Oct 15; 13(20):6168-74.
    View in: PubMed
    Score: 0.066
  52. Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer. 2007 Oct 01; 121(7):1520-8.
    View in: PubMed
    Score: 0.066
  53. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15; 179(4):2493-500.
    View in: PubMed
    Score: 0.065
  54. Martinson JA, Tenorio AR, Montoya CJ, Al-Harthi L, Gichinga CN, Krieg AM, Baum LL, Landay AL. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr; 120(4):526-35.
    View in: PubMed
    Score: 0.064
  55. Nichani AK, Dar MA, Krieg AM, Mirakhur KK, Kaushik RS, Griebel PJ, Manuja A, Townsend HG, Babiuk LA, Mutwiri GK. Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. Vet Immunol Immunopathol. 2007 Feb 15; 115(3-4):357-68.
    View in: PubMed
    Score: 0.062
  56. Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet Immunol Immunopathol. 2007 Jan 15; 115(1-2):24-34.
    View in: PubMed
    Score: 0.062
  57. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006 Sep-Oct; 29(5):558-68.
    View in: PubMed
    Score: 0.061
  58. Jurk M, Kritzler A, Schulte B, Tluk S, Schetter C, Krieg AM, Vollmer J. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol. 2006 Jul; 36(7):1815-26.
    View in: PubMed
    Score: 0.061
  59. Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M, Krieg AM. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine. 2006 Aug 28; 24(35-36):6155-62.
    View in: PubMed
    Score: 0.060
  60. Nichani AK, Mena A, Kaushik RS, Mutwiri GK, Townsend HG, Hecker R, Krieg AM, Babiuk LA, Griebel PJ. Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. Oligonucleotides. 2006; 16(1):58-67.
    View in: PubMed
    Score: 0.059
  61. McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol. 2006; 311:155-78.
    View in: PubMed
    Score: 0.059
  62. Butler JE, Francis DH, Freeling J, Weber P, Krieg AM. Antibody repertoire development in fetal and neonatal piglets. IX. Three pathogen-associated molecular patterns act synergistically to allow germfree piglets to respond to type 2 thymus-independent and thymus-dependent antigens. J Immunol. 2005 Nov 15; 175(10):6772-85.
    View in: PubMed
    Score: 0.058
  63. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol. 2005 Nov; 79(22):14355-70.
    View in: PubMed
    Score: 0.058
  64. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005 Sep 23; 19(14):1473-9.
    View in: PubMed
    Score: 0.057
  65. Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother. 2006 May; 55(5):515-27.
    View in: PubMed
    Score: 0.057
  66. Abel K, Wang Y, Fritts L, Sanchez E, Chung E, Fitzgerald-Bocarsly P, Krieg AM, Miller CJ. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol. 2005 May; 12(5):606-21.
    View in: PubMed
    Score: 0.056
  67. Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E. Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol. 2005 Mar 15; 69(6):981-91.
    View in: PubMed
    Score: 0.055
  68. Speiser DE, Li?nard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar; 115(3):739-46.
    View in: PubMed
    Score: 0.055
  69. Rees DG, Gates AJ, Green M, Eastaugh L, Lukaszewski RA, Griffin KF, Krieg AM, Titball RW. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 2005 Feb; 65(2):87-95.
    View in: PubMed
    Score: 0.055
  70. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
    View in: PubMed
    Score: 0.054
  71. Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol. 2004 Oct 15; 173(8):5148-55.
    View in: PubMed
    Score: 0.054
  72. Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology. 2004 Oct; 113(2):212-23.
    View in: PubMed
    Score: 0.054
  73. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004 Oct 01; 173(7):4433-42.
    View in: PubMed
    Score: 0.054
  74. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004 Aug 13; 22(23-24):3136-43.
    View in: PubMed
    Score: 0.053
  75. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004 Aug 01; 64(15):5074-7.
    View in: PubMed
    Score: 0.053
  76. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun. 2004 Feb; 72(2):949-57.
    View in: PubMed
    Score: 0.051
  77. Jurk M, Schulte B, Kritzler A, Noll B, Uhlmann E, Wader T, Schetter C, Krieg AM, Vollmer J. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004; 209(1-2):141-54.
    View in: PubMed
    Score: 0.051
  78. Utaisincharoen P, Kespichayawattana W, Anuntagool N, Chaisuriya P, Pichyangkul S, Krieg AM, Sirisinha S. CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol. 2003 Apr; 132(1):70-5.
    View in: PubMed
    Score: 0.048
  79. Lenert P, Yi AK, Krieg AM, Stunz LL, Ashman RF. Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. Antisense Nucleic Acid Drug Dev. 2003; 13(3):143-50.
    View in: PubMed
    Score: 0.048
  80. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 05; 32(5):1212-22.
    View in: PubMed
    Score: 0.045
  81. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol. 2002 Feb 01; 168(3):1212-8.
    View in: PubMed
    Score: 0.045
  82. Krieg AM. From A to Z on CpG. Trends Immunol. 2002 Feb; 23(2):64-5.
    View in: PubMed
    Score: 0.045
  83. Pontarollo RA, Rankin R, Babiuk LA, Godson DL, Griebel PJ, Hecker R, Krieg AM, van Drunen Littel-van den Hurk S. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Vet Immunol Immunopathol. 2002 Jan 01; 84(1-2):43-59.
    View in: PubMed
    Score: 0.044
  84. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg AM, Endres S, Hartmann G. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. Eur J Immunol. 2001 Dec; 31(12):3525-34.
    View in: PubMed
    Score: 0.044
  85. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 01; 167(9):4878-86.
    View in: PubMed
    Score: 0.044
  86. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct; 31(10):3026-37.
    View in: PubMed
    Score: 0.044
  87. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood. 2001 Aug 15; 98(4):1217-25.
    View in: PubMed
    Score: 0.043
  88. Lenert P, Stunz L, YI AK, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev. 2001 Aug; 11(4):247-56.
    View in: PubMed
    Score: 0.043
  89. Krug A, Rothenfusser S, Hornung V, Jahrsd?rfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul; 31(7):2154-63.
    View in: PubMed
    Score: 0.043
  90. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb; 3(1):15-24.
    View in: PubMed
    Score: 0.042
  91. Pichyangkul S, Yongvanitchit K, Kum-arb U, Krieg AM, Heppner DG, Walsh DS. Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods. 2001 Jan 01; 247(1-2):83-94.
    View in: PubMed
    Score: 0.041
  92. Jahrsd?rfer B, Hartmann G, Racila E, Jackson W, M?hlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol. 2001 Jan; 69(1):81-8.
    View in: PubMed
    Score: 0.041
  93. Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15; 165(12):6889-95.
    View in: PubMed
    Score: 0.041
  94. Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol. 2000 Dec 01; 165(11):6244-51.
    View in: PubMed
    Score: 0.041
  95. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 01; 165(11):6278-86.
    View in: PubMed
    Score: 0.041
  96. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000 Jan 15; 164(2):944-53.
    View in: PubMed
    Score: 0.039
  97. Krieg AM. Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000; 22(1-2):97-105.
    View in: PubMed
    Score: 0.039
  98. Krieg AM. A possible cause of joint destruction in septic arthritis. Arthritis Res. 1999; 1(1):3-4.
    View in: PubMed
    Score: 0.038
  99. Chu RS, Askew D, Noss EH, Tobian A, Krieg AM, Harding CV. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 01; 163(3):1188-94.
    View in: PubMed
    Score: 0.038
  100. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert PH, Krieg AM, Siegrist CA. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 01; 162(3):1611-7.
    View in: PubMed
    Score: 0.036
  101. Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998 Nov 15; 92(10):3730-6.
    View in: PubMed
    Score: 0.036
  102. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15; 161(6):3042-9.
    View in: PubMed
    Score: 0.035
  103. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 01; 161(5):2428-34.
    View in: PubMed
    Score: 0.035
  104. Weeratna R, Brazolot Millan CL, Krieg AM, Davis HL. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Aug; 8(4):351-6.
    View in: PubMed
    Score: 0.035
  105. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15; 89(8):2994-8.
    View in: PubMed
    Score: 0.032
  106. Yi AK, Hornbeck P, Lafrenz DE, Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol. 1996 Dec 01; 157(11):4918-25.
    View in: PubMed
    Score: 0.031
  107. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15; 156(12):4570-5.
    View in: PubMed
    Score: 0.030
  108. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 06; 374(6522):546-9.
    View in: PubMed
    Score: 0.028
  109. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
    View in: PubMed
    Score: 0.025
  110. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
    View in: PubMed
    Score: 0.018
  111. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Aug 20; 26(24):3979-86.
    View in: PubMed
    Score: 0.018
  112. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007; 12(5):741-51.
    View in: PubMed
    Score: 0.016
  113. Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol. 2006 Dec 15; 177(12):8701-7.
    View in: PubMed
    Score: 0.016
  114. Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006 Oct; 34(10):1403-12.
    View in: PubMed
    Score: 0.015
  115. Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol. 2006 Aug 01; 177(3):1670-8.
    View in: PubMed
    Score: 0.015
  116. Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, Sandler AD. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg. 2006 Aug; 41(8):1361-8.
    View in: PubMed
    Score: 0.015
  117. Montoya CJ, Jie HB, Al-Harthi L, Mulder C, Pati?o PJ, Rugeles MT, Krieg AM, Landay AL, Wilson SB. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol. 2006 Jul 15; 177(2):1028-39.
    View in: PubMed
    Score: 0.015
  118. Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol. 2005 Jan; 35(1):273-81.
    View in: PubMed
    Score: 0.014
  119. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004 Aug; 72(8):4494-502.
    View in: PubMed
    Score: 0.013
  120. Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA, Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res. 2004; 10(4):247-51.
    View in: PubMed
    Score: 0.013
  121. Hirunpetcharat C, Wipasa J, Sakkhachornphop S, Nitkumhan T, Zheng YZ, Pichyangkul S, Krieg AM, Walsh DS, Heppner DG, Good MF. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine. 2003 Jun 20; 21(21-22):2923-32.
    View in: PubMed
    Score: 0.012
  122. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct; 11(5):333-40.
    View in: PubMed
    Score: 0.011
  123. Chen Y, Zhang J, Moore SA, Ballas ZK, Portanova JP, Krieg AM, Berg DJ. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int Immunol. 2001 Aug; 13(8):1013-20.
    View in: PubMed
    Score: 0.011
  124. Schlueter AJ, Krieg AM, de Vries P, Li X. Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. J Interferon Cytokine Res. 2001 Aug; 21(8):621-9.
    View in: PubMed
    Score: 0.011
  125. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001 Mar; 69(3):1643-9.
    View in: PubMed
    Score: 0.010
  126. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22; 19(7-8):950-7.
    View in: PubMed
    Score: 0.010
  127. Davis HL, Suparto II, Weeratna RR, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Smits W, Sajuthi DD. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000 Mar 17; 18(18):1920-4.
    View in: PubMed
    Score: 0.010
  128. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15553-8.
    View in: PubMed
    Score: 0.009
  129. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998 Jan 15; 160(2):870-6.
    View in: PubMed
    Score: 0.008
  130. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17; 186(10):1623-31.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.